Therapeutic strategies impacting cancer cell glutamine metabolism

Future Medicinal Chemistry

Volumn 5, Issue 14, 2013, Pages 1685-1700

  Lukey, Michael J ^a   Wilson, Kristin F ^a   Cerione, Richard A ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; ACIVICIN; AMMONIA; ANTINEOPLASTIC AGENT; AZASERINE; BIS 2 (5 PHENYL ACETAMIDO 1,2,4 THIADIAZOYL)ETHYL SULFIDE; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NUCLEOTIDE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADAPTATION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CARBOXYLATION; CELL METABOLISM; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG MECHANISM; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; HUMAN; NAUSEA; NEUROTOXICITY; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; GLUTAMINASE; GLUTAMINE; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84884548852     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.130     Document Type: Review

References (124)

1. Warburg O. Origin of cancer cells. Science 123(3191), 309-314 (1956).
2. Warburg O. Respiratory impairment in cancer cells. Science 124(3215), 269-270 (1956).
3. Warburg O, Posener K, Negelein E. On the metabolism of carcinoma cells. Biochemische Zeitschrift 152, 309-344 (1924).
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324(5930), 1029-1033 (2009).
5. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11(2), 85-95 (2011).
6. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7(1), 11-20 (2008).
7. Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu. Rev. Nutr. 15, 133-159 (1995).
8. DeBerardinis RJ, Cheng T. Q's next: The diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29(3), 313-324 (2010).
9. Wise DR, Thompson CB. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem. Sci. 35(8), 427-433 (2010).
10. Daye D, Wellen KE. Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 23(4), 362-369 (2012).
11. Newsholme P Why is l-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J. Nutr. 131(9 Suppl.), 2515S-2522S; discussion 2523S-2514S (2001).
12. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science 122(3168), 501-514 (1955).
13. Wise DR, DeBerardinis RJ, Mancuso A et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA 105(48), 18782-18787 (2008).
14. Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim. Biophys. Acta 1825(1), 111-116 (2012).
15. Aledo JC, Gomez-Fabre PM, Olalla L, Marquez J. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm. Genome 11(12), 1107-1110 (2000).
16. Szeliga M, Obara-Michlewska M. Glutamine in neoplastic cells: Focus on the expression and roles of glutaminases. Neurochem. Int. 55(1-3), 71-75 (2009).
17. Marquez J, de la Oliva AR, Mates JM, Segura JA, Alonso FJ. Glutaminase: A multifaceted protein not only involved in generating glutamate. Neurochem. Int. 48(6-7), 465-471 (2006).
18. Gomez-Fabre PM, Aledo JC, Del Castillo-Olivares A et al. Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem. J. 345(Pt 2), 365-375 (2000).
19. Elgadi KM, Meguid RA, Qian M, Souba WW, Abcouwer SF. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol. Genomics 1(2), 51-62 (1999).
20. Mates JM, Segura JA, Martin-Rufian M, Campos-Sandoval JA, Alonso FJ, Marquez J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr. Mol. Med. 13(4), 514-534 (2013).
21. Porter LD, Ibrahim H, Taylor L, Curthoys NP. Complexity and species variation of the kidney-type glutaminase gene. Physiol. Genomics 9(3), 157-166 (2002).
22. Cassago A, Ferreira AP, Ferreira IM et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc. Natl Acad. Sci. USA 109(4), 1092-1097 (2012).
23. Wang JB, Erickson JW, Fuji R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18(3), 207-219 (2010).
24. Thangavelu K, Pan CQ, Karlberg T et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc. Natl Acad. Sci. USA 109(20), 7705-7710 (2012).
25. Gao P, Tchernyshyov I, Chang TC et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239), 762-765 (2009).
26. Reynolds MR, Lane AN, Robertson B et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene doi:10.1038/onc.2012.635 (2013) (Epub ahead of print).
27. Gaglio D, Metallo CM, Gameiro PA et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011).
28. Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS ONE 4(3), e4715 (2009).
29. Carr EL, Kelman A, Wu GS et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J. Immunol. 185(2), 1037-1044 (2010).
30. Son J, Lyssiotis CA, Ying H et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496(7443), 101-105 (2013).
31. Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res. 25(3), 375-383 (2012).
32. Metallo CM, Gameiro PA, Bell EL et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481(7381), 380-384 (2012).
33. Mullen AR, Wheaton WW, Jin ES et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481(7381), 385-388 (2012).
34. Wise DR, Ward PS, Shay JE et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl Acad. Sci. USA 108(49), 19611-19616 (2011).
35. Gameiro PA, Yang J, Metelo AM et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 17(3), 372-385 (2013).
36. Cheong H, Lu C, Lindsten T, Thompson CB. Therapeutic targets in cancer cell metabolism and autophagy. Nat. Biotechnol. 30(7), 671-678 (2012).
37. Vander Heiden MG. Targeting cancer metabolism: A therapeutic window opens. Nat. Rev. Drug Discov. 10(9), 671-684 (2011).
38. van der Vos KE, Eliasson P, Proikas-Cezanne T et al. Modulation of glutamine metabolism by the PI(3)K-PKB-FOXO network regulates autophagy. Nat. Cell. Biol. 14(8), 829-837 (2012).
39. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: The past, the present and recommendations for the future. Clin. Pharmacokinet. 44(4), 367-393 (2005).
40. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated l-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 96(5), 1709-1715 (2000).
41. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 18(2), 107-112 (2004).
42. Darmaun D, Welch S, Rini A, Sager BK, Altomare A, Haymond MW. Phenylbutyrate-induced glutamine depletion in humans: Effect on leucine metabolism. Am. J. Physiol. 274(5 Pt 1), E801-E807 (1998).
43. Thibault A, Cooper MR, Figg WD et al. A Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 54(7), 1690-1694 (1994).
44. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006).
45. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin. Cancer Biol. 15(4), 254-266 (2005).
46. Hassanein M, Hoeksema MD, Shiota M et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin. Cancer Res. 19(3), 560-570 (2013).
47. Esslinger CS, Cybulski KA, Rhoderick JF. Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg. Med. Chem. 13(4), 1111-1118 (2005).
48. Nicklin P, Bergman P, Zhang B et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136(3), 521-534 (2009).
49. Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am. J. Physiol. Cell Physiol. 293(1), C55-C63 (2007).
50. Todorova VK, Kaufmann Y, Luo S, Klimberg VS. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother. Pharmacol. 67(2), 285-291 (2011).
51. Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol. Ther. 46(2), 243-271 (1990).
52. Griffiths M, Keast D, Patrick G, Crawford M, Palmer TN. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro. Int. J. Biochem. 25(12), 1749-1755 (1993).
53. Mueller C, Al-Batran S, Jaeger E et al. A Phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-l-norleucine (DON) in patients with advanced refractory solid tumors. J. Clin. Oncol. 26(15) (2008).
54. Robinson MM, McBryant SJ, Tsukamoto T et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4- thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406(3), 407-414 (2007).
55. Hartwick EW, Curthoys NP. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase. J. Enzyme Inhib. Med. Chem. 27(6), 861-867 (2012).
56. DeLaBarre B, Gross S, Fang C et al. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 50(50), 10764-10770 (2011).
57. Shukla K, Ferraris DV, Thomas AG et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J. Med. Chem. 55(23), 10551-10563 (2012).
58. Katt WP, Ramachandran S, Erickson JW, Cerione RA. Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Mol. Cancer Ther. 11(6), 1269-1278 (2012).
59. Wilson KF, Erickson JW, Antonyak MA, Cerione RA. Rho GTPases and their roles in cancer metabolism. Trends Mol. Med. 19(2), 74-82 (2013).
60. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273(23), 14484-14494 (1998).
61. Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 150(6), 1196-1208 (2012).
62. Fuchs BC, Perez JC, Suetterlin JE, Chaudhry SB, Bode BP. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 286(3), G467-G478 (2004).
63. Duran RV, Oppliger W, Robitaille AM et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol. Cell 47(3), 349-358 (2012).
64. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10(11), 868-880 (2011).
65. Bunpo P, Dudley A, Cundiff JK, Cavener DR, Wek RC, Anthony TG. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent l-asparaginase. J. Biol. Chem. 284(47), 32742-32749 (2009).
66. Metallo CM, Vander Heiden MG. Metabolism strikes back: Metabolic flux regulates cell signaling. Genes Dev. 24(24), 2717-2722 (2010).
67. Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. Circ. Res. 107(2), 171-185 (2010).
68. Wellen KE, Lu C, Mancuso A et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 24(24), 2784-2799 (2010).
69. Donadio AC, Lobo C, Tosina M et al. Antisense glutaminase inhibition modifies the O-GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells. J. Cell Biochem. 103(3), 800-811 (2008).
70. Weinberg F, Hamanaka R, Wheaton WW et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107(19), 8788-8793 (2010).
71. Rhoads JM, Argenzio RA, Chen W et al. l-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Am. J. Physiol. 272(5 Pt 1), G943-953 (1997).
72. Larson SD, Li J, Chung DH, Evers BM. Molecular mechanisms contributing to glutamine-mediated intestinal cell survival. Am. J. Physiol. Gastrointest. Liver Physiol. 293(6), G1262-G1271 (2007).
73. Kozak M. An analysis of vertebrate mRNA sequences: Intimations of translational control. J. Cell Biol. 115(4), 887-903 (1991).
74. Satheesha S, Cookson VJ, Coleman LJ et al. Response to mTOR inhibition: Activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol. Cancer 10, 19 (2011).
75. Simpson NE, Tryndyak VP, Pogribna M, Beland FA, Pogribny IP. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics 7(12), 1413-1420 (2012).
76. Inoue J, Ito Y, Shimada S et al. Glutamine stimulates the gene expression and processing of sterol regulatory element binding proteins, thereby increasing the expression of their target genes. FEBS J. 278(15), 2739-2750 (2011).
77. Prickett TD, Samuels Y. Molecular pathways: Dysregulated glutamatergic signaling pathways in cancer. Clin. Cancer Res. 18(16), 4240-4246 (2012).
78. Le MN, Chan JL, Rosenberg SA et al. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J. Invest. Dermatol. 130(9), 2240-2249 (2010).
79. Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal. 3(119), ra31 (2010).
80. Cheong H, Lindsten T, Thompson CB. Autophagy and ammonia. Autophagy 8(1), 122-123 (2012).
81. Dang CV, Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells? Cell Cycle 9(19), 3884-3886 (2010).
82. Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle 9(19), 3921-3932 (2010).
83. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178(1), 93-105 (2007).
84. Weber G, Prajda N, Lui MS et al. Multi-enzyme-targeted chemotherapy by acivicin and actinomycin. Adv. Enzyme Regul. 20, 75-96 (1982).
85. Wyngaarden JB. Regulation of purine biosynthesis and turnover. Adv. Enzyme Regul. 14, 25-42 (1976).
86. Cory JG, Cory AH. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: Asparaginase treatment in childhood acute lymphoblastic leukemia. In Vivo 20(5), 587-589 (2006).
87. Krejci O, Starkova J, Otova B et al. Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by l-asparaginase in TEL/AML1-positive leukaemic cells. Leukemia 18(3), 434-441 (2004).
88. Chang WK, Yang KD, Shaio MF. Lymphocyte proliferation modulated by glutamine: Involved in the endogenous redox reaction. Clin. Exp. Immunol. 117(3), 482-488 (1999).
89. Horig H, Spagnoli GC, Filgueira L et al. Exogenous glutamine requirement is confined to late events of T cell activation. J. Cell Biochem. 53(4), 343-351 (1993).
90. Roth E, Oehler R, Manhart N et al. Regulative potential of glutamine - relation to glutathione metabolism. Nutrition 18(3), 217-221 (2002).
91. Colombo SL, Palacios-Callender M, Frakich N et al. Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc. Natl Acad. Sci. USA 108(52), 21069-21074 (2011).
92. DeBerardinis RJ, Mancuso A, Daikhin E et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104(49), 19345-19350 (2007).
93. Cheng T, Sudderth J, Yang C et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl Acad. Sci. USA 108(21), 8674-8679 (2011).
94. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 69(20), 7986-7993 (2009).
95. Le A, Lane AN, Hamaker M et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15(1), 110-121 (2012).
96. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J. Biol. Chem. 259(10), 6215-6221 (1984).
97. Thornburg JM, Nelson KK, Clem BF et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 10(5), R84 (2008).
98. Beuster G, Zarse K, Kaleta C et al. Inhibition of alanine aminotransferase in silico and in vivo promotes mitochondrial metabolism to impair malignant growth. J. Biol. Chem. 286(25), 22323-22330 (2011).
99. Holleran AL, Briscoe DA, Fiskum G, Kelleher JK. Glutamine metabolism in AS-30D hepatoma cells. Evidence for its conversion into lipids via reductive carboxylation. Mol. Cell Biochem. 152(2), 95-101 (1995).
100. Seltzer MJ, Bennett BD, Joshi AD et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70(22), 8981-8987 (2010).
101. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274), 739-744 (2009).
102. Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J. Cell Physiol. 215(3), 593-602 (2008).
103. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43(2), 143-181 (2006).
104. Mates JM, Segura JA, Alonso FJ, Marquez J. Oxidative stress in apoptosis and cancer: An update. Arch. Toxicol. 86(11), 1649-1665 (2012).
105. Bunpo P, Murray B, Cundiff J, Brizius E, Aldrich CJ, Anthony TG. Alanyl-glutamine consumption modifies the suppressive effect of l-asparaginase on lymphocyte populations in mice. J. Nutr. 138(2), 338-343 (2008).
106. Chaudhry FA, Reimer RJ, Edwards RH. The glutamine commute: Take the N line and transfer to the A. J. Cell Biol. 157(3), 349-355 (2002).
107. Gaisler-Salomon I, Miller GM, Chuhma N et al. Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: Relevance to schizophrenia. Neuropsychopharmacology 34(10), 2305-2322 (2009).
108. Masson J, Darmon M, Conjard A et al. Mice lacking brain/kidney phosphate-activated glutaminase have impaired glutamatergic synaptic transmission, altered breathing, disorganized goal-directed behavior and die shortly after birth. J. Neurosci. 26(17), 4660-4671 (2006).
109. Gaisler-Salomon I, Wang Y, Chuhma N et al. Synaptic underpinnings of altered hippocampal function in glutaminase-deficient mice during maturation. Hippocampus 22(5), 1027-1039 (2012).
110. El Hage M, Masson J, Conjard-Duplany A, Ferrier B, Baverel G, Martin G. Brain slices from glutaminase-deficient mice metabolize less glutamine: A cellular metabolomic study with carbon 13 NMR. J. Cereb. Blood Flow Metab. 32(5), 816-824 (2012).
111. Bae N, Wang Y, Li L, Rayport S, Lubec G. Network of brain protein level changes in glutaminase deficient fetal mice. J. Proteomics 80, 236-249 (2013).
112. Curthoys NP. Role of mitochondrial glutaminase in rat renal glutamine metabolism. J. Nutr. 131(9 Suppl.), 2491S-2495S; discussion 2496S-2497S (2001).
113. Frezza C, Pollard PJ, Gottlieb E. Inborn and acquired metabolic defects in cancer. J. Mol. Med. (Berl.) 89(3), 213-220 (2011).
114. Michelakis ED, Sutendra G, Dromparis P et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2(31), 31ra34 (2010).
115. Vander Heiden MG. Targeting cell metabolism in cancer patients. Sci. Transl. Med. 2(31), 31ed1 (2010).
116. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl Acad. Sci. USA 107(16), 7455-7460 (2010).
117. Suzuki S, Tanaka T, Poyurovsky MV et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl Acad. Sci. USA 107(16), 7461-7466 (2010).
118. Szeliga M, Obara-Michlewska M, Matyja E et al. Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia 57(9), 1014-1023 (2009).
119. Qing G, Li B, Vu A et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22(5), 631-644 (2012).
120. Rajagopalan KN, DeBerardinis RJ. Role of glutamine in cancer: Therapeutic and imaging implications. J. Nucl. Med. 52(7), 1005-1008 (2011).
121. Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin. Oncol. 38(1), 55-69 (2011).
122. Lieberman BP, Ploessl K, Wang L et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J. Nucl. Med. 52(12), 1947-1955 (2011).
123. Qu W, Oya S, Lieberman BP et al. Preparation and characterization of l-[5-11C]-glutamine for metabolic imaging of tumors. J. Nucl. Med. 53(1), 98-105 (2012).
124. Qu W, Zha Z, Ploessl K et al. Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors. J. Am. Chem. Soc 133(4), 1122-1133 (2011).